W189 - Exploring the Role of Monoclonal Antibody Therapy and Lipid Metabolic Alteration in Human Respiratory Syncytial Virus and Herpes Simplex Virus Type 1

Wednesday, June 25, 2025

7:30am - 7:30pm East Coast USA Time

MF

Mónica A. Farías, N/A, n/a

Postdoctoral Research
Instituto Milenio de Inmunología e Inmunoterapia, Pontificia Universidad Católica de Chile
Santiago, Region Metropolitana, Chile
CA

Catalina A. Andrade, None

Millennium Institute on Immunology and Immunotherapy. Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile., Chile
FC

Felipe A. Cancino

Millennium Institute on Immunology and Immunotherapy. Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile.
AN

Areli J. Navarro

Millennium Institute on Immunology and Immunotherapy. Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile.
RL

Ricardo A. Loaiza

Millennium Institute on Immunology and Immunotherapy. Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile.
LR

Linmar Rodríguez-Guilarte

Millennium Institute on Immunology and Immunotherapy. Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile.
JM

José T. Muñoz

Millennium Institute on Immunology and Immunotherapy. Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile.
LD

Luisa F. Duarte

Centro de Medicina Regenerativa, Facultad de Medicina, Clínica Alemana-Universidad del Desarrollo.
IP

Ignacio A. Pastén-Ferrada

Millennium Institute on Immunology and Immunotherapy. Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile.
AS

Abel A. Soto

Millennium Institute on Immunology and Immunotherapy. Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile.
ET

Eduardo I. Tognarelli

Ungraduated student
Millennium Institute on Immunology and Immunotherapy. Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile.
Santiago, Region Metropolitana, Chile
AC

Almendra A. Castillo

Millennium Institute on Immunology and Immunotherapy. Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile.
MR

Maximiliano J. Ramm

Facultad de Farmacia, Universidad de Concepción.
BA

Barbara N. Alarcón

Facultad de Farmacia, Universidad de Concepción
JC

José L. Cordero

Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile.
SS

Sergio San Martín

Grupo Interdisciplinario de Biotecnología Marina (GIBMAR), Centro de Biotecnología, Universidad de Concepción.
NM

Natalia Muñoz-Durango

Millennium Institute on Immunology and Immunotherapy. Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile.
MP

Magdalena S. Pizarro-Ortega

Millennium Institute on Immunology and Immunotherapy. Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile.
BD

Benjamín Diethelm-Varela

Millennium Institute on Immunology and Immunotherapy. Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile.
AP

Alejandra Pereira-Serrano

Millennium Institute on Immunology and Immunotherapy. Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile.
RR

Robinson A. Ramírez

Millennium Institute on Immunology and Immunotherapy. Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile.
JC

José L. Chávez

Millennium Institute on Immunology and Immunotherapy. Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile.
CA

Cristian Agurto-Muñoz

Grupo Interdisciplinario de Biotecnología Marina (GIBMAR), Centro de Biotecnología, Universidad de Concepción
AR

Angello Retamal-Díaz

Millennium Institute on Immunology and Immunotherapy. Centro de Investigación en Inmunología y Biotecnología Biomédica de Antofagasta, Facultad de Ciencias del Mar y de Recursos Biológicos, Universidad de Antofagasta.
NB

Nelson P. Barrera

Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile.
LB

Luis Bustamante

Facultad de Farmacia, Universidad de Concepción.
KB

Karen Bohmwald

Instituto de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad Autónoma de Chile.
JS

Jorge A. Soto

Facultad de Ciencias de la Vida, Universidad Andrés Bello.
SB

Susan M. Bueno

Millennium Institute on Immunology and Immunotherapy. Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile.
PG

Pablo A. González

Millennium Institute on Immunology and Immunotherapy. Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile.
AK

Alexis M. Kalergis

Millennium Institute on Immunology and Immunotherapy. Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile.

Abstract Text: Human respiratory syncytial virus (hRSV) and herpes simplex virus type 1 (HSV-1) are prevalent pathogens with significant morbidity. hRSV causes acute lower respiratory infections in infants, while HSV-1 establishes lifelong infections through neuronal latency. Both viruses lack approved vaccines for at-risk populations, emphasizing the need for innovative therapeutic approaches. This study explores a monoclonal antibody (mAb) therapy against hRSV and the role of lipid metabolism in the pathogenesis of both viruses. We developed four high-affinity humanized anti-N-hRSV mAb clones and tested them in a BALB/c murine model. Treatment with anti-N-hRSV mAb reduced pulmonary and long-term neurological pathologies associated with hRSV. To understand the mechanism of long-term neurological pathologies, we also examined the hRSV impact on central nervous system (CNS) cells, focusing on neutral lipid metabolism, which is linked to neurodegenerative pathologies. In vitro studies revealed that hRSV alters the neutral lipid composition of CNS cells and their lipid gene expression. Likewise, we have found that HSV-1, a neurotropic virus, disrupts lipid metabolism in neuronal cells, inducing lipid droplet (LD) formation. Inhibiting lipid uptake reduced HSV-1 propagation and restored MHC-I expression. These findings align with our dendritic cell (DC) studies, where HSV-1 infection reduced lipid catabolism and increased lipid synthesis pathways, promoting triglyceride and ceramide accumulation, which impaired DC function. Pharmacological inhibition of lipid synthesis pathways in HSV-1-infected DCs reduced LD accumulation and viral replication, improving DC viability and immune response. These results suggest that anti-N-hRSV mAb and lipid metabolism may be promising targets for antiviral therapies against hRSV and HSV-1.